Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
PETHEMA Foundation
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06175702CT.gov Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL | — | Not Yet Recruiting | — | — | — |
NCT04722848CT.gov Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | — | Active Not Recruiting | — | — | — |
NCT04688983CT.gov Study in Adult Ph-positive ALL | — | Unknown | — | — | — |
NCT02538926CT.gov Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | — | Withdrawn | — | — | — |
NCT01383447CT.gov Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT00702403CT.gov Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | — | Completed | — | — | — |
NCT00061945CT.gov Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00025415CT.gov Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | — | Completed | — | — | — |
NCT00036738CT.gov Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adult Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Imatinib (this asset) | PETHEMA Foundation | P3 | BB · 64 |
| Mercaptopurine Anhydrous | Shanxi Bethune Hospital | P4 | A |
| Dexasone | Shanxi Bethune Hospital | P4 | BBB |
| Cytarabine | PETHEMA Foundation | P4 | BBB |
| Cyclophosphamide | The First Affiliated Hospital of Zhengzhou University | P4 | BBB |
| Asparaginase | Institute of Hematology & Blood Diseases Hospital, China | P4 | BBB |
| Vindesine | Shanxi Bethune Hospital | P4 | BBB |
| (+)-Vincristine | PETHEMA Foundation | P4 | BBB |
| Methotrexate | PETHEMA Foundation | P4 | BBB |
+42 more in the Adult Acute Lymphoblastic Leukemia cohort
Other indications for Imatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | — | P2 | BB · 71 |
| Chronic Myeloid Leukemia | — | P2 | BB · 71 |
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Imatinib in Adult Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/imatinib-adult-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →